The National Pharmaceutical Group's share of the 2 billion-pound compound Sanofi is only 30%.

Pharma.com August 24 - August 21, CDE official website data show that the national pharmaceutical group Guorui Pharmaceuticals' Ebeshatan hydrochlorine tablets 4 imitation listing applications were undertaken.
Erbeshatan hydrochlorochlorophenicol is more than 2 billion heavy-weight varieties in cardiovascular drugs, but also the first round of collection (4 plus 7, alliance expansion) catalog varieties, with the domestic generic drugs have entered the market, the market share of the original research Sanofi "falling."
Figure 1: Registration of Ebershatan hydrochlorochloride tablets by Guorui Pharmaceuticals, China National Pharmaceutical Group Source: CDE Official Website Ebershatan Hydrochlorochlorophene for the treatment of primary hypertension, Minanet data show in Chinese cities in 2019 Public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal sales of more than 2.7 billion, the current market related products have dispersive tablets, ordinary tablets, capsules, of which tablets (dispersion tablets, ordinary tablets) total market share of more than 90%.
Figure 2: Enterprise competition pattern of Ebershatan hydrochlorochloride in 2019 Source: Minet China's public medical institutions terminal competition pattern From the enterprise pattern, the market share of the original research Sanofi (Ebersatan hydrochlorochloride tablets) fell from 40% in 2015 to about 35% in 2019, The market share of Nanjing Zhengda Tianqing Pharmaceuticals (Alliance Expansion) increased from 33% in 2015 to 34% in 2019, while that of Huahai Pharmaceutical Co., Ltd. (4-7 exclusive winning bid and Alliance Expansion winning bid) increased from 8% in 2015 to 13% in 2019.
, despite Sanofi's big price cuts as the league expanded, has not been able to withstand the positive impact of generic drugs in the country.
Table 1: Applications for the generic listing of Ebershatan hydrochlorochlorophene currently under review from 2018 Source: Miennet MED2.0 China Drug Review Database Minet Data show that, in addition to the new entry of Chinese medicine, the current trial of Ebersha Tan hydrochloride tablets 4 imitation listing applications involving up to 6 enterprises, has passed the consistent evaluation of enterprises including Zhejiang Aino Biopharmaceuticals, Nanjing Zhengda Tianqing Pharmaceuticals, Zhejiang Huahai Pharmaceuticals, Hubei Jingjiangyuan Pharmaceuticals, Hunan Fangsheng Pharmaceuticals, Hebei Longhai Pharmaceuticals.
source: CDE official website, Minet database review data statistics as of August 21, 2020, if there are errors, please point out.
.